Introduction
============

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal (GI) disorders afflicting between 10--15% of the global population.[@b1-jnm-24-096] Primary symptoms associated with IBS include abdominal pain and irregular bowel movements that, based upon the predominant symptom pattern, may be utilized to subdivide the syndrome into 3 classifications: diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), and mixed IBS (IBS-M).[@b2-jnm-24-096] However, the subtype of IBS that an individual is classified does not necessarily remain static; patients can evolve over time from diarrheic or mixed type to constipative. The chronic and erratic nature of IBS can lead to a multitude of secondary effects, such as depression, anxiety, poor quality of life, insomnia, and sexual dysfunction.[@b3-jnm-24-096] Using the current diagnostic model for IBS, the Rome IV criteria, symptoms must be present for 3 months or longer before diagnoses can be established.[@b4-jnm-24-096] Other disorders with IBS-like symptoms that should be excluded include celiac disease, inflammatory bowel disease (IBD), malabsorptive disorders, pelvic floor disorders, and colon cancer. Further, once diagnosed, treatment for IBS patients may be mostly palliative in nature with dietary changes and pharmacological agents to alleviate symptoms in some patients.[@b5-jnm-24-096] The chronic symptoms, costly process, and lack of a fully satisfactory or curative treatment contribute to a significantly decreased quality of life for those affected.

Despite the prevalence of IBS and the disease burden it places on individual patients as well as the healthcare system, the pathophysiology of the disorder remains enigmatic, with some exceptions. Results from independent familial and twin studies suggest that IBS may have a genetic etiology.[@b6-jnm-24-096] These findings have led to significant interest in genetic characteristics that may be leveraged to diagnose IBS. For example, this approach has exhibited success in identifying specific alleles in 2 of the most prevalent forms of IBD, namely Crohn's disease (CD) and ulcerative colitis (UC).[@b7-jnm-24-096] Genetic polymorphisms have also been discovered that may be associated with IBS; thus IBS appears to be a complex and multifactorial disorder with possible genetic components similar to CD and UC.[@b8-jnm-24-096]

DNA microarrays have been used to study gene expression in colonic tissue samples from IBD, UC, and CD patients.[@b9-jnm-24-096]--[@b11-jnm-24-096] DNA microarrays have also been employed to characterize gene expression in IBS,[@b12-jnm-24-096]--[@b14-jnm-24-096] albeit somewhat less completely. Based on genes identified via microarray results, and predictive analysis of microarrays evaluation, a test utilizing a series of 32 probes representing differentially expressed genes was constructed that purportedly afforded 70% accuracy in distinguishing between mucosal tissues derived from IBS and non-IBS individuals.[@b14-jnm-24-096] Identification of additional differentially expressed genes may lead to development of a modified assay with higher accuracy, and further insight into the molecular foundation of IBS. Thus, a test to probe expression of IBS-relevant genes, as well as other biomarkers, may afford better discrimination between symptomatic and asymptomatic individuals, and is highly desirable.[@b11-jnm-24-096],[@b13-jnm-24-096],[@b14-jnm-24-096]

Irregularities in serotonergic metabolism have also been hypothesized as potential causal factors for IBS.[@b15-jnm-24-096] Although commonly associated with central nervous function, the majority of serotonin (95%) is synthesized within the GI tract.[@b16-jnm-24-096] Of this serotonin, over 90% is produced by enterochromaffin cells whereas the remainder is synthesized by neurons within the myenteric plexus.[@b17-jnm-24-096] Two genes significantly involved in serotonin metabolism display decreased levels of expression in IBS: the serotonin transporter and the synthetic rate-limiting enzyme, tryptophan hydroxylase 1 (TPH1).[@b18-jnm-24-096] Other studies also point to disordered enteric serotonergic signaling in the pathophysiology of IBS,[@b19-jnm-24-096],[@b20-jnm-24-096] although a clear mechanism has yet to emerge. Nonetheless, a serotonergic model for IBS has shown some efficacy in the design of novel therapeutic regimens for IBS. Selective serotonin reuptake inhibitors are serotonin transporter inhibitors originally designed as antidepressants which have also exhibited potential to alleviate IBS symptoms.[@b21-jnm-24-096]

Upstream regulation of serotoninergic metabolic processes may also be involved in IBS pathogenesis. For example, while commonly associated with its role in Ca^2+^/PO~4~^3−^ homeostasis, vitamin D is crucial in the modulation of a variety of other pathways, including those involved in anti-inflammatory and immunomodulatory activity.[@b22-jnm-24-096] Thus, vitamin D has been proposed as a potential treatment for IBS[@b23-jnm-24-096] as well as IBD.[@b24-jnm-24-096] Moreover, in a recent report, the production of the rate-limiting enzyme in serotonin production, TPH, was significantly stimulated by the active hormonal vitamin D metabolite, 1,25-dihydroxyvitamin D (1,25D), in serotonergic neurons.[@b25-jnm-24-096]

If IBS is linked to an imbalance in serotonin production, vitamin D could play a role in IBS pathogenesis and may provide novel insights into new modes of IBS management. Further, given the previously-discussed possible genetic etiology of IBS, we postulated that the vitamin D profile and individual transcriptome patterns from our patient cohort could be explored in an attempt to identify a more efficacious and cost-effective diagnostic model for IBS. Thus, this study analyzed physiological levels of vitamin D and the transcriptional pattern of serotonergic gene expression within IBS and control patient populations and identified other genes as potential novel IBS biomarkers.

Materials and Methods
=====================

Sample Acquisition and Storage
------------------------------

A total of 29 patients consisting of 28 non-Hispanic Caucasians and 1 Asian participant were recruited over the course of this study. Mucosal tissue samples were obtained from 24 subjects as described by Costello et al.[@b10-jnm-24-096] These samples included individuals suffering from untreated IBS and individuals that did not display IBS symptoms (which served as the experimental control). Samples were obtained from the sigmoid colon (25 cm measured from withdrawal). All research was approved by the Arizona State University IRB (No. 1106006538) and the Marshfield Clinic Research Foundation IRB (No. YAL10308) and all subjects were consented using a written informed consent form that was approved by the IRB. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

RNA Isolation: Cell Culture-based
---------------------------------

HCT-116 colorectal cancer cells (male-derived) obtained from the American Type Culture Collection (Manassas, VA, USA) were passaged in DMEM/high glucose media supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells were plated at 800 000 cells/well in 6 well plates and treated with either 10 nM 1,25D or ethanol vehicle and incubated in a humidified environment composed of 5% CO~2~ at 37ºC for 24 hours. Total RNA was extracted from each well using the Aurum total RNA mini kit (Bio-Rad, Hercules, CA, USA) following the manufacturer's protocol. Spectroscopy was employed to obtain A~260~ and A~280~ values to quantify and assess RNA yield/quality.

RNA Isolation: Tissue-based
---------------------------

Total RNA was obtained using the Aurum total RNA mini kit (Bio-Rad) and manufacturer's protocol. Tissue samples were resuspended in 700 μL of Aurum cell lysis buffer and the cells were lysed via sonication. Spectroscopy was utilized to assess quantity and quality of the RNA. RNA derived from non-IBS control patients were combined into an RNA pool from 8 control samples prior to downstream application.

Microarray Analysis: Tissue-based
---------------------------------

RNA quality and concentration was determined on a Bioanalyzer (Agilent, Santa Clara, CA, USA) and NanoDrop spectrophotometer (ThermoFisher, Waltham, MA, USA). One-color labeling reactions were prepared using the Agilent one-color protocol (version 6.5) with 400 ng total RNA input. Then, 400 ng of total RNA with the appropriate concentration of RNA spike-in controls was converted into double stranded cDNA using an oligo (dT) primer linked to the T7 promoter sequence and Moloney murine leukemia virus reverse transcriptase. The double stranded cDNA was then in vitro transcribed by T7 RNA polymerase, which simultaneously amplifies and incorporates cyanine 3-labeled cytidine triphosphate into the resulting cRNA. Labeled cRNA was then purified using RNeasy columns (Qiagen, Germantown, MD, USA) and the labeling efficiency determined by the NanoDrop spectrophotometer. Next, the labeled cRNA was fragmented and placed on the SurePrint G3 Human GE microarray (Ambry Genetics, Aliso Viejo, CA, USA) and hybridized at 65°C for approximately 17 hours. The arrays were washed and scanned at 3 μM resolution on an Agilent G2565CA high-resolution scanner. Finally, data processing was performed using Agilent's Feature Extraction software (version 11.01.1) using protocol GE1_1100_Jul11 and the 60K grid file 039494_D\_F_20120628.

Identification of Differentially Expressed Genes and Gene Ontology/Pathway Enrichment Analysis
----------------------------------------------------------------------------------------------

Background-corrected intensities were normalized by the "limma" package[@b26-jnm-24-096] in R. Differentially expressed genes between groups were obtained by combining the lists of features with *P*-values \< 0.05 from the "limma" linear model *t* test, the Mann-Whitney U test, and the Student's *t* test. The selected 1564 features were then mapped to genes, and the list of 858 unique genes were subjected to ontology/pathway analysis and visualized by using the "ClueGO"[@b27-jnm-24-096] and "ReactomeFI"[@b28-jnm-24-096] packages in Cytoscape,[@b29-jnm-24-096] from which enriched terms with *P*-value \< 0.05 were identified.

Quantitative Real-time Polymerase Chain Reaction
------------------------------------------------

DNase-treated total RNA (1 μg) was reverse-transcribed via an iScript cDNA Synthesis kit (Bio-Rad) to prepare 20 μL of first strand cDNA. Real-time polymerase chain reaction (PCR) reactions were prepared by adding 1.5 μL of cDNA to 5 μL FastStart Universal SYBR Green Master Mix (Rox) (Roche Applied Science, Indianapolis, IN, USA) and primers for a total volume of 10 μL. Reactions were performed in 96 well plates in a BioRad CFX96 thermal cycler using a 40-cycle profile. Data analysis was performed using the comparative ΔΔCt method as the means of relative quantitation, normalized to an endogenous reference (GAPDH) and relative to a calibrator (normalized Ct value from vehicle-treated cells) and expressed as 2^−ΔΔCt^. The primers utilized during PCR experimentation were as follows:

  ----------------------- ------------------------------
  Human TDRD6-forward     5′-AACACCTACACTCTGAAAGCC-3′
  Human TDRD6-reverse     5′-CGGTTAAATCTCCATCACCTCC-3′
  Human MSR1-forward      5′-GCTCAATGACAGCTTTGCTTC-3′
  Human MSR1-reverse      5′-CCAATGAGAGGGATGAGAACTG-3′
  Human EPHA3-forward     5′-CACCTTTGAGATTGATGCCG-3′
  Human EPHA3-reverse     5′-GATGCTATTTCTGGAGGTCCG-3′
  Human FLT4-forward      5′-AGGCATAGACAAGAAAGCGG-3
  Human FLT4-reverse      5′-TGTAAAACACCTGGCCTCC-3′
  Human ZDHHC15-forward   5′-CTGAGGTCCAGAAGCAGATG-3′
  Human ZDHHC15-reverse   5′-TGGCTTGATCAGATGACACC-3′
  Human TPH1-forward      5′-TAAGGAGAACAAAGACCATTCC-3′
  Human TPH1-reverse      5′-TTTCTTCTTTTTGATTTTCGGG-3′
  ----------------------- ------------------------------

Analysis of Vitamin D Metabolite Levels
---------------------------------------

Measurement of 25-hydroxyvitamin D (25\[OH\]D) concentrations from patient serum was performed by Heartland Assays (Ames, IA, USA). A competitive chemiluminescence immunoassay was employed for assessment of 25(OH)D concentrations, as described previously.[@b30-jnm-24-096]

Statistical Methods
-------------------

Real-time PCR data are reported as means ± SD. Two-sided Student's *t* tests were used to measure statistical differences with *P*-values less than 0.05 considered significant. The 25(OH)D concentrations from patient serum are reported as means (± SD), and a two-sided Student's *t* test was used to measure statistical differences with *P*-values less than 0.05 considered significant. The competitive chemiluminescence immunoassay employed for assessment of 25(OH)D concentrations included quality assurance and quality control measures such as a pooled serum sample analyzed with batches of study samples to monitor analytical precision and identify possible laboratory shifts over time, as well as testing duplicates in different batches. The coefficient of variation was less than 7% for 25(OH)D analyses. All analyses were conducted in a blinded fashion. Microarray data was processed using Agilent's Feature Extraction software (version 11.01.1). Data generated from each sample were subsequently used to identify differentially expressed genes (*P* ≤ 0.05). Data were normalized using limma.[@b26-jnm-24-096]

Results
=======

Evaluation of Potential Irritable Bowel Syndrome Biomarkers
-----------------------------------------------------------

Samples contained one cohort of 18 asymptomatic individuals and another group of 11 patients who had been diagnosed with IBS using the Rome III criteria. Information regarding patient age, sex, IBS status, subtype, and serum 25(OH)D levels is summarized in [Table 1](#t1-jnm-24-096){ref-type="table"}. The trimmed mean for 25(OH)D concentration (lowest/highest value excepted) in all IBS patients was 38.9 ng/mL versus 47.4 ng/mL in control subjects, with a median value of 40.7 ng/mL in all IBS patients and 46.5 ng/mL in the control cohort. Moreover, the mean 25(OH)D level in the IBS-D subtype was 25.9 ng/mL versus 47.7 ng/mL in all control patients (*P* \< 0.03). These data from the current pool of IBS/control patients revealed a trend towards lower vitamin D levels within the IBS population, and perhaps specifically in IBS-D patients.

DNA microarray analyses were performed using colonic RNA derived from IBS and asymptomatic sample populations. Analysis of the raw microarray data established a series of 858 genes/biomarkers that display differential expression ([Fig. 1](#f1-jnm-24-096){ref-type="fig"}). A tabular list of the top 200 biomarkers exhibiting differential expression between the 2 groups is provided in [Supplementary Table 1](#s1-jnm-24-096){ref-type="supplementary-material"}. This set of genetic features shows considerable functional diversity (eg, folate reception, Golgi-ER transport, lipid-intake, etc) and underscores the complexity of the potential genetic foundation of IBS.

Analysis of Biochemical Pathways Potentially Influenced by Irritable Bowel Syndrome
-----------------------------------------------------------------------------------

To visualize effects of distinct gene expression patterns on biochemical pathways, gene ontology (GO) enrichment analysis was performed on the differentially expressed set of genes, with the top 30 enriched GO terms listed in [Table 2](#t2-jnm-24-096){ref-type="table"}. Genes were grouped into pathways in which at least 5 members shared similar interactions ([Fig. 2](#f2-jnm-24-096){ref-type="fig"}). Of particular interest in the current study are the 2 pathways ([Fig. 2A and 2C](#f2-jnm-24-096){ref-type="fig"}) that coincide with serotonin metabolism, as these 2 pathways possess the highest number of shared functions of any groups.

Evaluation of Tryptophan Hydroxylase-1 Expression Within the Irritable Bowel Syndrome Cohort
--------------------------------------------------------------------------------------------

Due to the prevalence of serotonergic pathways within our GO analysis, we aimed at exploring the potential link between serotonin and IBS in further detail. Quantitative real-time PCR was employed to assess the expression of TPH1 due to its role as the rate-limiting biosynthetic enzyme involved in serotonin production within the enterochromaffin cells of the gut[@b17-jnm-24-096] and its proposed link with IBS pathophysiology.[@b18-jnm-24-096] We compared TPH1 expression in individual gut tissue samples of the IBS cohort to the expression profile obtained from a pooled RNA sample comprised of 8 individuals from the asymptomatic cohort selected at random. The results from this analysis for each IBS cohort sample were plotted against each patient's serum vitamin D concentration ([Fig. 3](#f3-jnm-24-096){ref-type="fig"}). Of the 11 IBS patients analyzed, 10 samples displayed decreased levels of TPH1 expression relative to the control RNA pool. Additionally, 80% of the IBS patients displayed *both* decreased TPH1 expression and 25(OH)D levels below 50 ng/mL (the clinical reference range in most laboratories for 25(OH)D is 20--100 ng/mL, with a preferred range of 30--60 ng/mL as vitamin D "sufficient"[@b31-jnm-24-096],[@b32-jnm-24-096]). While no clear pattern was observed that could differentiate between the TPH1 expression levels or 25(OH)D concentrations and IBS subtypes (C, D, or M), the data in [Figure 3](#f3-jnm-24-096){ref-type="fig"} (combined with the 25\[OH\]D data in [Table 1](#t1-jnm-24-096){ref-type="table"}) suggest lower levels of serum vitamin D and/or colonic TPH1 expression as potential biomarkers for IBS.

Vitamin D Affects the Expression of Several Putative Irritable Bowel Syndrome Biomarkers in Colonic Epithelial Cell-lines
-------------------------------------------------------------------------------------------------------------------------

Colorectal cells (HCT-116) were treated with 10^−8^ M 1,25D for 24 hours and the mRNA levels of 5 putative IBS genetic biomarkers were analyzed using real-time PCR ([Fig. 4](#f4-jnm-24-096){ref-type="fig"}). These genes were selected from an analysis of the DNA microarray data and represent genes with statistically significant, differential regulation in the IBS patients with high fold activation or repression relative to control patients ([Supplemental Table 2](#s1-jnm-24-096){ref-type="supplementary-material"}). Of the 5 IBS biomarker candidate genes tested for regulation by 1,25D, 3 genes (TDRD6, EPHA3, and FLT4) were influenced by the presence of 10^−8^ M vitamin D, while 2 genes (MSR1 and ZDHHC15) were unchanged. Given the role of FLT4 in both angiogenesis and lymphangiogenesis,[@b33-jnm-24-096] the involvement of EPHA3 in axonal migration and pathfinding,[@b34-jnm-24-096] and the hypothesized function of TDRD6 in spliceosome function,[@b35-jnm-24-096] more research is necessary to determine their possible function in IBS pathogenesis. Nonetheless, regardless of the exact mechanism whereby these genes might influence IBS pathophysiology, when tested in response to 1,25D ([Fig. 4](#f4-jnm-24-096){ref-type="fig"}), the expression of TDRD6 was repressed 0.54 fold (*P* \< 0.005), EPHA3 was induced 2.23 fold (*P* \< 0.0005), and FLT4 mRNA was attenuated 0.67 fold (*P* \< 0.05). Significantly, DNA microarray data ([Supplementary Table 2](#s1-jnm-24-096){ref-type="supplementary-material"}) indicated that the IBS cohort displayed increased TDRD6 and FLT4 expression and decreased EPHA3 expression. Thus, the direction of gene regulation by 1,25D in colonic cells is "opposite" to that observed in IBS patients, suggesting that vitamin D treatment may help reverse the pathological direction of biomarker gene expression in IBS.

Discussion
==========

DNA microarray analysis revealed 858 features that exhibited differential expression between an IBS sample population and asymptomatic control population. These results provide evidence to support the hypothesis that IBS may be founded upon a genetic or transcriptome basis, as has been suggested previously.[@b14-jnm-24-096] Similar to a previous study,[@b14-jnm-24-096] our list of putative IBS biomarkers ([Supplementary Table 1](#s1-jnm-24-096){ref-type="supplementary-material"}) contains genes that are both up-regulated and down-regulated in IBS patients versus healthy controls. We also obtained high concordance between genes identified in the microarray and those subsequently assessed by real-time PCR, similar to the work of Aerssens et al.[@b14-jnm-24-096] However, we observed a higher percentage of IBS up-regulated genes (40%) than Aerssens et al[@b14-jnm-24-096] (25%). Some of these differentially expressed genes may prove useful as screening biomarkers that could be utilized to improve the performance of the Rome IV diagnostic model. We propose that the expression pattern of a subset of these genes may consistently produce a characteristic IBS genetic "fingerprint" ([Fig. 1](#f1-jnm-24-096){ref-type="fig"}) that could be used as an effective screening tool for rapid diagnosis of IBS-afflicted individuals.

In addition to serving as potential biomarkers, many of the genes located within the differentially expressed gene group may play an etiological role in the IBS pathological state. Analysis of individual gene functions and complex polygenetic interactions is a key first step in discovering a potential causative association between specific gene expression patterns and IBS pathophysiology. Gene ontology interaction analysis was performed to provide a broad overview of our complex microarray dataset. Our analysis revealed that genes involved in serotonin metabolism were well represented in the differentially expressed gene pool. An IBS disease model in which an imbalance of serotonin production or responsiveness may play a key role in IBS pathogenesis has been proposed, and it is possible that defective serotonin signaling is a common feature in the pathogenesis of functional bowel diseases. Pharmacological intervention strategies with serotonergic agents have been successfully employed in some patients as treatment modalities.[@b36-jnm-24-096] Real-time PCR analysis of the rate-limiting enzyme (TPH1) in gut serotonin synthesis was performed to determine whether IBS patients exhibited a decreased store of GI serotonin. This analysis revealed that 10 of the 11 IBS patients tested exhibited decreased levels of TPH1 relative to a non-IBS sample population, although another study[@b37-jnm-24-096] found a statistically insignificant trend towards elevated TPH1 expression in IBS patients.

The active hormonal metabolite of vitamin D has been shown to modulate serotonin production within neural[@b25-jnm-24-096] and colonic tissue (data not shown). In fact, vitamin D has been proposed as a potential treatment for IBS.[@b38-jnm-24-096],[@b39-jnm-24-096] Due to the relative abundance of vitamin D responsive elements (VDREs) in hundreds of vitamin D regulated genes throughout the genome,[@b40-jnm-24-096] we postulated that expression of some IBS candidate biomarker genes may be influenced by the presence of the active hormonal metabolite of vitamin D, 1,25-dihydroxyvitamin D~3~ (1,25D).[@b41-jnm-24-096] The manner in which this potential regulation occurs and the specific genes involved in IBS pathophysiology may suggest possible new approaches to treatment.

We recently identified functional VDREs in the human TPH1 gene.[@b25-jnm-24-096] Taking this into account and considering the potential linkage between IBS and abnormal serotonin metabolism, we examined whether IBS patients exhibited lower serum levels of vitamin D. Nine of the eleven patient samples that were tested displayed 25(OH)D levels below 50 ng/mL (the range of vitamin D "sufficiency" has been previously defined as 30--60 ng/mL, with the most optimal levels ≥ 50 ng/mL[@b32-jnm-24-096]). However, given our small sample size, this finding could have been affected by individual variance in sun-exposure, supplement intake, and overall body fat composition. Nonetheless, serum 25(OH)D levels are recognized as a reliable biomarker of human vitamin D status, and reflect the ability of tissues to synthesize the active hormonal metabolite of vitamin D, 1,25D which regulates gene expression via the vitamin D receptor.

In addition, given that vitamin D regulates the expression of a vast array of genes,[@b42-jnm-24-096] we postulated that lower vitamin D levels may explain some of the differential expression patterns observed in our DNA microarray analyses. To test this hypothesis, HCT-116 colonic cells were treated with 10^−8^ M 1,25D, and real-time PCR was used to analyze the response of 5 different putative IBS biomarkers (TDRD6, MSR1, EPHA3, FLT4, and ZDHC115) which were selected via a combination of DNA microarray analysis and real-time PCR ([Supplementary Table 2](#s1-jnm-24-096){ref-type="supplementary-material"}). The results of this analysis revealed that 1,25D regulates a subset of potential IBS genes (TDRD6, EPHA3, and FLT4) in a manner that offsets the altered expression patterns within our IBS patient cohort ([Fig. 4](#f4-jnm-24-096){ref-type="fig"}). This suggests that vitamin D may help ameliorate IBS symptoms by reversing the pathological gene expression of IBS biomarkers.

Serotonin release by enterochromaffin cells embedded within the GI mucosa is used to modulate the strength of smooth muscle contraction and, in turn, GI motility.[@b43-jnm-24-096] High levels of serotonin release correlate with high levels of GI motility, and low levels of serotonin release correlate with low levels of GI motility.[@b44-jnm-24-096],[@b45-jnm-24-096] Conventionally, IBS-C would be associated with depressed serotonin production, IBS-M with intermediate or alternating serotonin production, and IBS-D with elevated serotonin production. However, 10 of the 11 IBS patient tissue samples analyzed in our cohort exhibited depressed levels of TPH1 expression relative to a sample population of control non-IBS RNA. Previously, we have measured the stimulation of serotonin production in response to vitamin D within the serotonergic cell line, RN46A-B14.[@b46-jnm-24-096] Thus, given that TPH1 mRNA was induced by 1,25D in the gut, it is likely that serotonin is produced in the colon in response to vitamin D, as well. Interestingly, when TPH1 expression and sera vitamin D content were plotted ([Fig. 3](#f3-jnm-24-096){ref-type="fig"}), a pattern that differentiates between different IBS subtypes was not readily apparent. One possible explanation for these observations is that the depressed levels of TPH1 in IBS-D patients may be predominantly the result of feedback repression of the TPH1 gene via elevated serotonin signaling, while lowered levels of TPH1 in IBS-C and/or IBS-M patients may be primarily the result of vitamin D insufficiency. Thus, the IBS pathological state may be correlated with dysregulated serotonin production, possibly secondary to (or in combination with) vitamin D deficiency. Moreover, during the administration of the current study, another clinical trial was published[@b47-jnm-24-096] that reported an IBS cohort with appreciably depressed serum 25(OH)D levels and a significant positive association between quality of life and circulating 25(OH)D concentrations after vitamin D supplementation. Interestingly, the IBS-C patients in this population were the most responsive to vitamin D supplementation in terms of a striking improvement across nearly all IBS symptoms.[@b47-jnm-24-096] Because IBS-C patients are thought to possess lower gut serotonin levels,[@b48-jnm-24-096] the responsiveness of these patients to vitamin D supplementation is consistent with the actions of vitamin D to raise gut TPH1/serotonin levels[@b25-jnm-24-096] and with our current hypothesis that vitamin D, via induction of the intestinal TPH1 gene, may play a role in IBS pathophysiology.

While this study was limited by its small sample size, our IBS cohort displayed a trend toward diminished serum vitamin D levels relative to our non-IBS control group. Further, we provide preliminary evidence that vitamin D may have the capacity to alleviate some IBS symptoms via regulation of IBS-specific genes, as well as to increase expression of TPH1[@b25-jnm-24-096] to drive enhanced gut serotonin production, particularly in IBS-C and/or IBS-M patients. However, communication between the central nervous system and the gut plays a tremendous role in the modulation of GI function in a relationship termed the gut-brain axis. Furthermore, recent research has shown that GI microbiota may significantly influence the gut-brain axis through neural, endocrine, and immune signaling and may possibly contribute to certain disease states.[@b49-jnm-24-096] Strong evidence exists that indicates the GI microbiome[@b50-jnm-24-096] may play a role in IBS,[@b51-jnm-24-096] that vitamin D signaling may also impact the gut microbiome,[@b52-jnm-24-096] and that gut microbiota regulate host serotonin biosynthesis.[@b53-jnm-24-096] Therefore, we are actively exploring interactions between vitamin D, serotonin metabolism and related gene expression, as well as the microbiome to develop additional diagnostic modalities and to further elucidate mechanistic paradigms in IBS.

Conclusion
==========

A total of 858 differentially expressed genes were identified, including differential expression of genes associated with serotonin metabolism. Analysis via real-time PCR revealed that IBS patient-derived RNA exhibited lower levels of TPH1, the enzyme that catalyzes the rate-limiting step in serotonin biosynthesis, relative to control non-IBS samples. Moreover, values for serum 25(OH)D concentrations across both the IBS and control sample populations revealed a trend towards lower vitamin D levels within the IBS cohort, particularly in the IBS-D subtype. Finally, the expression of select IBS genetic biomarkers was shown to be modulated by vitamin D. These results suggest that IBS pathogenesis and pathophysiology may involve dysregulated serotonin production and/or vitamin D insufficiency.
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![Differential gene expression in irritable bowel syndrome (IBS). A heat map illustrating 858 genetic features with differential expression levels between IBS and asymptomatic populations, with *P*-values \< 0.05 as determined through the Mann-Whitney U test. Color and intensity correlated with the expression patterns for individual biomarkers. Blue is indicative of lower levels of expression while red is indicative of higher levels.](jnm-24-096f1){#f1-jnm-24-096}

![Gene ontology, pathways, and interactions involved with the genes identified to be differentially expressed between the irritable bowel syndrome and the asymptomatic control cohort. (A--E) The interactions shown include only those that possessed 5 or more functions. SA, sinoatrial; Pi, inorganic phosphate.](jnm-24-096f2){#f2-jnm-24-096}

![Expression of tryptophan hydroxylase-1 (TPH1) is reduced in irritable bowel syndrome (IBS). Real-time polymerase chain reaction was employed to compare expression patterns observed in IBS patient-derived RNA with expression patterns found in a pooled RNA sample from 8 asymptomatic patients. Fold values were plotted against the sera vitamin D content of each individual IBS patient. The region consisting of values that correlate with both depressed TPH1 expression and sera vitamin D concentrations below 50 ng/mL is shaded gray. Note: one IBS patient possessed low (0.27-fold) TPH1 expression but vitamin D levels were not measured, thus this patient is not included in the graph. The data are presented as a ratio of IBS patient:non-IBS control pool to assess the relative gene expression of TPH1 in the IBS cohort. 25(OH)D, 25-hydroxyvitamin D; IBS-D, diarrhea-predominant IBS; IBS-M, mixed IBS; IBS-C, constipation-predominant IBS.](jnm-24-096f3){#f3-jnm-24-096}

![Effect of 1,25-dihydroxyvitamin D~3~ (1,25D) on the expression of irritable bowel syndrome (IBS)-candidate gene mRNA in human colonic cells. Cells were treated with 10^−8^ M 1,25D for 24 hours, and mRNA levels determined by real-time polymerase chain reaction. Fold induction by 1,25D is shown on the ordinate for the indicated genes. CYP24A1 (+) is a positive control gene known to be upregulated by vitamin D. Data are representative of at least 3 independent experiments with 3--6 replicates in each group. \**P* \< 0.05; \*\**P* \< 0.005; \*\*\**P* \< 0.0005. Preliminary experiments in the noncancerous cell line, HEK-293, reveal similar findings (data not shown). EtOH, ethanol.](jnm-24-096f4){#f4-jnm-24-096}

###### 

Cohort Sample Characteristics

  Sample ID                                           Classification   IBS subtype   Age   Gender   Race        Serum 25(OH)D (ng/mL)
  --------------------------------------------------- ---------------- ------------- ----- -------- ----------- -----------------------
  IBS-006                                             Control          N/A           55    F        Caucasian   32.7
  IBS-010                                             Control          N/A           54    M        Caucasian   13.8
  IBS-012                                             Control          N/A           50    F        Caucasian   30.6
  IBS-016                                             Control          N/A           52    F        Caucasian   50.1
  IBS-022                                             Control          N/A           60    F        Caucasian   63.6
  IBS-026                                             Control          N/A           53    M        Caucasian   44.8
  IBS-027                                             Control          N/A           50    M        Caucasian   24.9
  IBS-056                                             Control          N/A           51    F        Asian       84.6
  IBS-017                                             Control          N/A           57    F        Caucasian   31.3
  IBS-019                                             Control          N/A           50    M        Caucasian   47.8
  IBS-030                                             Control          N/A           47    M        Caucasian   51.3
  IBS-043                                             Control          N/A           54    F        Caucasian   63.1
  IBS-045                                             Control          N/A           50    F        Caucasian   45.2
  IBS-011[a](#tfn1-jnm-24-096){ref-type="table-fn"}   Control          N/A           50    F        Caucasian   87.2
  IBS-020[a](#tfn1-jnm-24-096){ref-type="table-fn"}   Control          N/A           47    M        Caucasian   52.5
  IBS-021[a](#tfn1-jnm-24-096){ref-type="table-fn"}   Control          N/A           49    F        Caucasian   60.3
  IBS-032[a](#tfn1-jnm-24-096){ref-type="table-fn"}   Control          N/A           50    F        Caucasian   32.7
  IBS-046[a](#tfn1-jnm-24-096){ref-type="table-fn"}   Control          N/A           51    F        Caucasian   42.4
  IBS-002                                             Case             IBS-D         56    F        Caucasian   ND
  IBS-003                                             Case             Unknown       49    F        Caucasian   48.0
  IBS-004                                             Case             IBS-M         51    F        Caucasian   23.2
  IBS-007                                             Case             IBS-M         53    F        Caucasian   45.5
  IBS-009                                             Case             IBS-D         58    M        Caucasian   35.8
  IBS-013                                             Case             IBS-C         57    F        Caucasian   81.8
  IBS-024                                             Case             IBS-M         51    M        Caucasian   60.8
  IBS-025                                             Case             IBS-D         55    M        Caucasian   25.7
  IBS-028                                             Case             IBS-D         55    F        Caucasian   16.1
  IBS-033                                             Case             IBS-M         46    F        Caucasian   26.1
  IBS-034                                             Case             IBS-M         41    F        Caucasian   46.0

Blood samples only.

IBS, irritable bowel syndrome; 25(OH)D, 25-hydroxyvitamin D; N/A, not applicable (due to control patient status); F, female; M, male; IBS-D, diarrhea-predominant IBS; IBS-M, mixed IBS; IBS-C, constipation-predominant IBS; ND, not determined.

A total of 29 patients were enrolled in this study.

###### 

Top 30 Enriched Gene Ontology Terms

  UNIQUE_ID        GO Term                                                                              Ontology Source                           Term *P*-value
  ---------------- ------------------------------------------------------------------------------------ ----------------------------------------- ----------------
  GO:0051610       serotonin uptake                                                                     GO_BiologicalProcess_20.03.2014_19h52     2.63E-04
  GO:0060633       negative regulation of transcription initiation from RNA polymerase II promoter      GO_BiologicalProcess_20.03.2014_19h52     9.12E-04
  GO:2000143       negative regulation of DNA-templated transcription, initiation                       GO_BiologicalProcess_20.03.2014_19h52     0.002682196
  REACTOME:19411   Type II Na+/Pi cotransporters                                                        REACTOME_21.03.2014                       0.002682196
  GO:0006772       thiamine metabolic process                                                           GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  GO:0014063       negative regulation of serotonin secretion                                           GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  GO:0019262       N-acetylneuraminate catabolic process                                                GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  GO:0022824       transmitter-gated ion channel activity                                               GO_MolecularFunction_20.03.2014_19h52     0.005256933
  GO:0022835       transmitter-gated channel activity                                                   GO_MolecularFunction_20.03.2014_19h52     0.005256933
  GO:0034056       estrogen response element binding                                                    GO_MolecularFunction_20.03.2014_19h52     0.005256933
  GO:0034154       toll-like receptor 7 signaling pathway                                               GO_ImmuneSystemProcess_20.03.2014_19h52   0.005256933
  GO:0051581       negative regulation of neurotransmitter uptake                                       GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  GO:0051611       regulation of serotonin uptake                                                       GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  GO:0051612       negative regulation of serotonin uptake                                              GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  GO:0086015       SA node cell action potential                                                        GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  GO:0086018       SA node cell to atrial cardiac muscle cell signalling                                GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  GO:2000467       positive regulation of glycogen (starch) synthase activity                           GO_BiologicalProcess_20.03.2014_19h52     0.005256933
  REACTOME:15551   Catecholamine biosynthesis                                                           REACTOME_21.03.2014                       0.005256933
  GO:0000711       meiotic DNA repair synthesis                                                         GO_BiologicalProcess_20.03.2014_19h52     0.030233082
  GO:0001587       Gq/11-coupled serotonin receptor activity                                            GO_MolecularFunction_20.03.2014_19h52     0.030233082
  GO:0003026       regulation of systemic arterial blood pressure by aorticarch baroreceptor feedback   GO_BiologicalProcess_20.03.2014_19h52     0.030233082
  GO:0003294       atrial ventricular junction remodeling                                               GO_BiologicalProcess_20.03.2014_19h52     0.030233082
  GO:0004964       luteinizing hormone receptor activity                                                GO_MolecularFunction_20.03.2014_19h52     0.030233082
  GO:0005335       serotonin:sodium symporter activity                                                  GO_MolecularFunction_20.03.2014_19h52     0.030233082
  GO:0005757       mitochondrial permeability transition pore complex                                   GO_CellularComponent_20.03.2014_19h52     0.030233082
  GO:0006585       dopamine biosynthetic process from tyrosine                                          GO_BiologicalProcess_20.03.2014_19h52     0.030233082
  GO:0010607       negative regulation of cytoplasmic mRNA processing body assembly                     GO_BiologicalProcess_20.03.2014_19h52     0.030233082
  GO:0010610       regulation of mRNA stability involved in response to stress                          GO_BiologicalProcess_20.03.2014_19h52     0.030233082
  GO:0010747       positive regulation of plasma membrane long-chain fatty acid transport               GO_BiologicalProcess_20.03.2014_19h52     0.030233082
  GO:0010904       regulation of UDP-glucose catabolic process                                          GO_BiologicalProcess_20.03.2014_19h52     0.030233082

GO, gene ontology.

Data are organized in order of increasing *P*-value.

[^1]: Deceased.
